PharmaTher Holdings Ltd. (OTCMKTS:PHRRF) Short Interest Update

PharmaTher Holdings Ltd. (OTCMKTS:PHRRF – Get Free Report) was the recipient of a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 8,311 shares, a decrease of 83.9% from the May 14th total of 51,769 shares. Based on an average trading volume of 266,185 shares, the short-interest ratio is presently 0.0 days.

PharmaTher Stock Performance

OTCMKTS:PHRRF traded down $0.00 during trading hours on Wednesday, reaching $0.04. The company had a trading volume of 56,490 shares, compared to its average volume of 176,071. The stock has a 50-day moving average of $0.05 and a two-hundred day moving average of $0.06. PharmaTher has a one year low of $0.04 and a one year high of $0.55.

Get PharmaTher alerts:

PharmaTher Company Profile

(Get Free Report)

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures.

Read More

• Five stocks we like better than PharmaTher
• Nebius Group’s £1.7 Billion UK Expansion Fuels Bullish Case Despite the Pullback
• An Analyst Just Raised Tesla’s Price Target by 227%—Here’s Why
• AST SpaceMobile’s SpaceX Catalyst Could Come With a Volatility Warning
• GameStop’s $2 Billion Buyback Sends a Confusing Signal to Investors

Receive News & Ratings for PharmaTher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaTher and related companies with MarketBeat.com's FREE daily email newsletter.